NEW YORK (GenomeWeb News) – Horizon Discovery and the University of Washington said today that they have entered into a pair of additional licensing agreements in the area of human gene targeting.

The new agreements give Cambridge, UK-based Horizon the exclusive right to commercialize inventions made by UW researcher David Russell, relating to the use of parvoviral vectors in human genome engineering.

In exchange, UW will be granted an undisclosed number of shares in Horizon and will receive ongoing product royalties from licensed products and services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.